Israel Englander Outlook Therapeutics, Inc. Transaction History

Millennium Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.22 - $0.66 $29,004 - $87,013	131,839 Added 91.72%	275,572 $107,000
Q2 2023 Aug 14, 2023	SELL	$1.02 - $1.89 $379,185 - $702,607	-371,750 Reduced 72.12%	143,733 $250,000
Q1 2023 May 15, 2023	BUY	$1.0 - $1.35 $341,279 - $460,726	341,279 Added 195.91%	515,483 $562,000
Q4 2022 Feb 14, 2023	BUY	$0.87 - $1.33 $35,981 - $55,006	41,358 Added 31.13%	174,204 $188,000
Q3 2022 Nov 14, 2022	SELL	$1.02 - $1.26 $160,801 - $198,637	-157,649 Reduced 54.27%	132,846 $162,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.17B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.